>Dr. Reddy's Laboratories Limited: Entered into an agreement with Teva Pharmaceuticals Inc. (“Teva”) under which the company would supply olanzapine 20 mg tablets to Teva.

■ Q3 FY12 Results Update
Dr. Reddy’s Lab. has reported consolidated net profit of Rs 5129.60 million for the quarter ended on December 31, 2011 as against Rs. 2731.40 million in the same quarter last year, an increase of 87.80%. It has reported net sales of Rs 27691.90 million for the quarter ended on December 31, 2011 as against Rs 18985.10 million in the same quarter last year, a rise of 45.86%. Total income grew by 45.22% to Rs. 27856.70 million from Rs.19183.00 million in the same quarter last year. During the quarter, it reported earnings of Rs 30.26 a share.


■ Net Sales & PAT growth
During the quarter, Net sales rose by 45.86% to Rs.27691.90 million from Rs.18985.10 in the same the quarter last year and the Total Profit for quarter ended December 2011 was Rs. 5129.60 million grew by 87.80% from Rs. 2731.40 million compared to same quarter last year.


■ EPS
Due to increase in equity capital the basic EPS of the company stood at Rs. 30.26 for the quarter ended December 2011 from Rs. 16.14 for the quarter ended December 2010.


 ■ Launched during the quarter
During the quarter, the Company received an approval and was awarded a 180-day period of marketing exclusivity from the U.S. FDA for olanzapine 20 mg tablets (generic version of Eli Lilly’s Zyprexa®20 mg) for sale in the United States. The Company had entered into an agreement with Teva Pharmaceuticals Inc. (“Teva”) under which the company would supply olanzapine 20 mg tablets to Teva.


To read the full report: DR REDDY
RISH TRADER